menu

Keeping Pace in Women’s Cancer: The Role of PARP Inhibitors in Ovarian Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer

close
0.25 credits
15 minutes
Keeping Pace in Women's Cancer: The Role of PARP Inhibitors in Ovarian Cancer
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    The approval of PARP inhibitors for maintaining response to chemotherapy and in recurrent disease has improved outcomes for patients. Additionally, ongoing and conclusive studies are paving the way for PARP inhibitor use earlier in therapy.

    This activity will discuss recent clinical trials and look at the paradigm shift with PARP inhibitors, specifically within the frontline setting. Also included is a look at how the approved and emerging PARP inhibitors can be used as monotherapy and in combination approaches.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Warner K. Huh, MD
    Professor and Division Director, Gynecologic Oncology
    Vice Chair, Gynecology
    University of Alabama at Birmingham
    Birmingham, AL

    Consulting Fees: Altum, Antiva, LI-COR

    Faculty:
    Deborah K. Armstrong, MD
    Professor of Oncology
    Professor of Gynecology and Obstetrics
    Johns Hopkins Kimmel Cancer Center
    Baltimore, MD

    Contracted Research: AstraZeneca, Clovis, Eisai/Morphotek, Pfizer, Syndax, Tesaro

    Robert L. Coleman, MD, FACOG, FACS
    Chief Scientific Officer
    US Oncology Research
    Houston, TX

    Consulting Fees: AbbVie, AstraZeneca, Clovis Oncology, Esperance, GamaMabs, Genmab, Janssen, Millennium, Merck, OncoMed, Pfizer, Roche/Genentech, Tesaro
    Contracted Research: AbbVie,AstraZeneca, Clovis Oncology, Esperance, Janssen, Merck, OncoMed, Roche/Genentech

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • William A. Mencia, MD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the rationale and clinical evidence on the utility and appropriate patient selection of approved PARP inhibitors in the maintenance setting and upon recurrence after chemotherapy.
    • Identify key recent clinical trial data to distinguish between approved and emerging PARP inhibitors and determine their utility in new clinical settings as monotherapy and in combination approaches.
  • Target Audience

    This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, pathologist, ob-gyns, and oncology nurse practitioners and physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from GSK.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The approval of PARP inhibitors for maintaining response to chemotherapy and in recurrent disease has improved outcomes for patients. Additionally, ongoing and conclusive studies are paving the way for PARP inhibitor use earlier in therapy.

    This activity will discuss recent clinical trials and look at the paradigm shift with PARP inhibitors, specifically within the frontline setting. Also included is a look at how the approved and emerging PARP inhibitors can be used as monotherapy and in combination approaches.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Warner K. Huh, MD
    Professor and Division Director, Gynecologic Oncology
    Vice Chair, Gynecology
    University of Alabama at Birmingham
    Birmingham, AL

    Consulting Fees: Altum, Antiva, LI-COR

    Faculty:
    Deborah K. Armstrong, MD
    Professor of Oncology
    Professor of Gynecology and Obstetrics
    Johns Hopkins Kimmel Cancer Center
    Baltimore, MD

    Contracted Research: AstraZeneca, Clovis, Eisai/Morphotek, Pfizer, Syndax, Tesaro

    Robert L. Coleman, MD, FACOG, FACS
    Chief Scientific Officer
    US Oncology Research
    Houston, TX

    Consulting Fees: AbbVie, AstraZeneca, Clovis Oncology, Esperance, GamaMabs, Genmab, Janssen, Millennium, Merck, OncoMed, Pfizer, Roche/Genentech, Tesaro
    Contracted Research: AbbVie,AstraZeneca, Clovis Oncology, Esperance, Janssen, Merck, OncoMed, Roche/Genentech

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • William A. Mencia, MD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Recognize the rationale and clinical evidence on the utility and appropriate patient selection of approved PARP inhibitors in the maintenance setting and upon recurrence after chemotherapy.
    • Identify key recent clinical trial data to distinguish between approved and emerging PARP inhibitors and determine their utility in new clinical settings as monotherapy and in combination approaches.
  • Target Audience

    This activity is designed to meet the educational needs of gynecologic oncologists, medical oncologists, pathologist, ob-gyns, and oncology nurse practitioners and physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from GSK.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/23/20